
Edwards Lifesciences Acquires BMEYE



Edwards

Critical Care portfolio expands to include non-invasive platform

Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, announced on October 10, 2012 that it has completed the acquisition of BMEYE B.V., a privately held Dutch company that specializes in the development of non-invasive technology for advanced hemodynamic monitoring. BMEYE's technology provides continuous, real-time information to clinicians and can be used in the surgical, intensive care, emergency room and cardiology settings.

"BMEYE's unique non-invasive technology platform complements our existing portfolio and will provide clinicians with critical, comprehensive hemodynamic monitoring information for a broader range of patients. Numerous studies have concluded that therapy guided by hemodynamic monitoring improves patient outcomes and reduces complications and lengths of hospital stays," said Carlyn Solomon, Edwards' corporate vice president, critical care and vascular. "This acquisition supports our ongoing commitment to build and strengthen our offerings for clinicians and patients, and reinforces our leadership in hemodynamic monitoring."

BMEYE's monitoring products work with a non-invasive finger cuff to measure continuous, real-time information on cardiac output, blood pressure, fluid responsiveness and other important hemodynamic parameters. Currently, BMEYE's products are approved for sale in the United States, throughout Europe and in several other countries.

Rob de Ree, chief executive officer of BMEYE said, "BMEYE has a solid history of developing innovative hemodynamic monitoring solutions. We look forward to joining the Edwards team to extend the reach of our existing products, and to continue to develop novel technologies to help clinicians and improve patient care worldwide."

While BMEYE's products have primarily been used by clinicians outside of the hospital, over the next 18 months, Edwards plans to further develop BMEYE's technology and integrate it into the Edwards EV1000 clinical platform for use in the acute care setting in hospitals.

The purchase price was €32.5 million (approximately \$42 million). Edwards expects the net earnings impact from this transaction to be immaterial in 2012, and slightly dilutive in 2013. Additional details will be forthcoming when the company provides 2013 financial guidance in December.

Source: Edwards Lifesciences Corporation

www.edwards.com

Published on : Mon, 22 Oct 2012